Role of bradykinin in renoprotective effects by angiotensin II type 1 receptor antagonist in salt-sensitive hypertension

Hypertension Research

Volumn 26, Issue 3, 2003, Pages 265-272

  Yokota, Kazuaki ^a   Kishida, Masayuki ^a   Ogura, Toshio ^a   Suzuki, Jiro ^a   Otsuka, Fumio ^a   Mimura, Yukari ^a   Takeda, Masaya ^a   Nakamura, Yoshio ^a   Makino, Hirofumi ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

Angiotensin II type 1 and 2 receptors; Bradykinin; Glomerulus; Nitric oxide; Prostaglandins

Indexed keywords

ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BRADYKININ; BRADYKININ B2 RECEPTOR ANTAGONIST; CANDESARTAN; CREATININE; NITRATE; NITRIC OXIDE; NITRITE; PROSTAGLANDIN E2; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; CREATININE CLEARANCE; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFECT; DRUG MECHANISM; GLOMERULOPATHY; GLOMERULOSCLEROSIS; HISTOPATHOLOGY; HYPERTENSION; KIDNEY INJURY; MALE; NONHUMAN; RAT; SALT INTAKE; SYSTOLIC BLOOD PRESSURE; URINARY EXCRETION;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BLOOD PRESSURE; BRADYKININ; HEART RATE; HYPERTENSION, RENAL; KIDNEY; MALE; NITRIC OXIDE; ORGAN SIZE; PROTEINURIA; RATS; RATS, INBRED DAHL; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ANGIOTENSIN, TYPE 2; RECEPTOR, BRADYKININ B2; TETRAZOLES; URINE;

EID: 0037360013     PISSN: 09169636     EISSN: None     Source Type: Journal    
DOI: 10.1291/hypres.26.265     Document Type: Article

References (47)

1. Weber MA: Interrupting the renin-angiotensin system: the role of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists in the treatment of hypertension. Am J Hypertens 1999; 12 (Suppl): 189S-194S.
2. Ma L, Fogo AB: Role of angiotensin II in glomerular injury. Semin Nephrol 2001; 21: 544-553.
3. Otsuka F, Yamauchi T, Ogura T, Takahashi M, Kageyama J, Makino H: Renal c-fos expression induced by angiotensin II is enhanced in spontaneously hypertensive rats. Life Sci 1998; 63: 2089-2095.
4. Gomez RA: Angiotensin receptors: relevance in development and disease states. Exp Nephrol 1994; 2: 259-268.
5. Inagami T, Guo DF, Kitami Y: Molecular biology of angiotensin II receptors: an overview. J Hypertens 1994; 12 (Suppl 10): S83-S94.
6. Weir MR, Henrich WL: Theoretical basis and clinical evidence for differential effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor subtype 1 blockers. Curr Opin Nephrol Hypertens 2000; 9: 403-411.
7. Bhoola KD, Figueroa CD, Worthy K: Bioregulation of kinins: kallikreins, kininogens, and kininases. Pharmacol Rev 1992; 44: 1-80.
8. Hall JM: Bradykinin receptors. Gen Pharmacol 1997; 28: 1-6.
9. Siragy HM: Evidence that intrarenal bradykinin plays a role in regulation of renal function. Am J Physiol 1993; 265: E648-E654.
10. Madeddu P, Parpaglia PP, Demontis MP, Varoni MV, Fattaccio MC, Glorioso N: Chronic inhibition of bradykinin B2-receptors enhances the slow vasopressor response to angiotensin II. Hypertension 1994; 23: 646-652.
11. Carey RM, Wang ZQ, Siragy HM: Update: role of the angiotensin type-2 (AT(2)) receptor in blood pressure regulation. Curr Hypertens Rep 2000; 2: 198-201.
12. Jalowy A, Schulz R, Dorge H, Behrends M, Heusch G: Infarct size reduction by AT1-receptor blockade through a signal cascade of AT2-receptor activation, bradykinin and prostaglandins in pigs. J Am Coll Cardiol 1998; 32: 1787-1796.
13. Otsuka F, Yamauchi T, Kataoka H, Mimura Y, Ogura T, Makino H: Effects of chronic inhibition of ACE and AT1 receptors on glomerular injury in Dahl salt-sensitive rats. Am J Physiol 1998; 274: R1797-R1806.
14. Otsuka F, Ogura T, Yamauchi T, et al: Chronic treatment with angiotensin II type 1 receptor antagonist suppresses glomerular activator protein-1 activity in salt-sensitive hypertensive rats. Kidney Blood Press Res 2000; 23: 35-41.
15. Siragy HM, de Gasparo M, El-Kersh M, Carey RM: Angiotensin-converting enzyme inhibition potentiates angiotensin II type 1 receptor effects on renal bradykinin and cGMP. Hypertension 2001; 38: 183-186.
16. Siragy HM, El-Kersh MA, De Gasparo M, Webb RL, Carey RM: Differences in AT2-receptor stimulation between AT1-receptor blockers valsartan and losartan quantified by renal interstitial fluid cGMP. J Hypertens 2002; 20: 1157-1163.
17. Bandeira-Melo C, Calheiros AS, Silva PM, Cordeiro RS, Teixeira MM, Martins MA: Suppressive effect of distinct bradykinin B2 receptor antagonist on allergen-evoked exudation and leukocyte infiltration in sensitized rats. Br J Pharmacol 1999; 127: 315-320.
18. Raij L, Azar S, Keane W: Mesangial immune injury, hypertension, and progressive glomerular damage in Dahl rats. Kidney Int 1984; 26: 137-143.
19. Bao G, Gohlke P, Unger T: Role of bradykinin in chronic antihypertensive actions of ramipril in different hypertension models. J Cardiovasc Pharmacol 1992; 20: S96-S99.
20. Linz W, Scholkens BA: A specific B2-bradykinin receptor antagonist HOE 140 abolishes the antihypertrophic effect of ramipril. Br J Pharmacol 1992; 105: 771-772.
21. Chen K, Zhang X, Dunham EW, Zimmerman BG: Kinin-mediated antihypertensive effect of captopril in deoxycorticosterone acetate-salt hypertension. Hypertension 1996; 27: 85-89.
22. Allen AM, Zhuo J, Mendelsohn FA: Localization of angiotensin AT1 and AT2 receptors. J Am Soc Nephrol 1999; 10(Suppl): S23-S29.
23. Ardaillou R: Angiotensin II receptors. J Am Soc Nephrol 1999; 10 (Suppl 11): S30-S39.
24. Yamada T, Horiuchi M, Dzau VJ: Angiotensin II type 2 receptor mediates programmed cell death. Proc Natl Acad Sci U S A 1996; 93: 156-160.
25. Goto M, Mukoyama M, Sugawara A, et al: Expression and role of angiotensin II type 2 receptor in the kidney and mesangial cells of spontaneously hypertensive rats. Hypertens Res 2002; 25: 125-133.
26. Horiuchi M, Hamai M, Cui TX, Iwai M, Minokoshi Y: Cross talk between angiotensin II type 1 and type 2 receptors: cellular mechanism of angiotensin type 2 receptor-mediated cell growth inhibition. Hypertens Res 1999; 22: 67-74.
27. Siragy HM, Inagami T, Ichiki T, Carey RM: Sustained hypersensitivity to angiotensin II and its mechanism in mice lacking the subtype-2 (AT2) angiotensin receptor. Proc Natl Acad Sci U S A 1999; 96: 6506-6511.
28. Gross V, Schunck WH, Honeck H, et al: Inhibition of pressure natriuresis in mice lacking the AT2 receptor. Kidney Int 2000; 57: 191-202.
29. Tsutsumi Y, Matsubara H, Masaki H, et al: Angiotensin II type 2 receptor overexpression activates the vascular kinin system and causes vasodilation. J Clin Invest 1999; 104: 925-935.
30. Emanueli C, Maestri R, Corradi D, et al: Dilated and failing cardiomyopathy in bradykinin B(2) receptor knockout mice. Circulation 1999; 100: 2359-2365.
31. Madeddu P, Emanueli C, Maestri R, et al: Angiotensin II type 1 receptor blockade prevents cardiac remodeling in bradykinin B(2) receptor knockout mice. Hypertension 2000; 35: 391-396.
32. Cervenka L, Maly J, Karasova L, et al: Angiotensin II-induced hypertension in bradykinin B2 receptor knockout mice. Hypertension 2001; 37: 967-973.
33. Hirawa N, Uehara, Y, Suzuki T, et al: Regression of glomerular injury by kallikrein infusion in Dahl salt-sensitive rats is a bradykinin B2-receptor-mediated event. Nephron 1999; 81: 183-193.
34. Yang W, Ando J, Korenaga R, Toyo-oka T, Kamiya A: Exogenous nitric oxide inhibits proliferation of cultured vascular endothelial cells. Biochem Biophys Res Commun 1994; 203: 1160-1167.
35. Garg UC, Hassid A: Nitric oxide-generating vasodilators inhibit mitogenesis and proliferation of BALB/C 3T3 fibroblasts by a cyclic GMP-independent mechanism. Biochem Biophys Res Commun 1990; 171: 474-479.
36. Bauer PM, Buga GM, Ignarro LJ: Role of p42/p44 mitogen-activated-protein kinase and p21waf1/cip1 in the regulation of vascular smooth muscle cell proliferation by nitric oxide. Proc Natl Acad Sci U S A 2001; 98: 12802-12807.
37. Garg UC, Hassid A: Inhibition of rat mesangial cell mitogenesis by nitric oxide-generating vasodilators. Am J Physiol 1989; 257: F60-F66.
38. Ohishi K, Carmines PK, Inscho EW, Navar LG: EDRF-angiotensin II interactions in rat juxtamedullary afferent and efferent arterioles. Am J Physiol 1992; 263: F900-F906.
39. Zhang H, Gaginella TS, Chen X, Cornwell DG: Action of bradykinin at the cyclooxygenase step in prostanoid synthesis through the arachidonic acid cascade. Agents Actions 1991; 34: 397-404.
40. McAllister BS, Leeb-Lundberg LM, Javors MA, Olson MS: Bradykinin receptors and signal transduction pathways in human fibroblasts: integral role for extracellular calcium. Arch Biochem Biophys 1993; 304: 294-301.
41. Burch RM: Bradykinin signal transduction in fibroblasts. Agents Actions 1992; 38 (Suppl): 87-92.
42. Gallagher AM, Yu H, Printz MP: Bradykinin-induced reductions in collagen gene expression involve prostacyclin. Hypertension 1998; 32: 84-88.
43. McAllister BS, Leeb-Lundberg F, Olson MS: Bradykinin inhibition of EGF- and PDGF-induced DNA synthesis in human fibroblasts. Am J Physiol 1993; 265: C477-C484.
44. Kataoka H, Otsuka F, Ogura T, et al: The role of nitric oxide and the renin-angiotensin system in salt-restricted Dahl rats. Am J Hypertens 2001; 14: 276-288.
45. Otsuka F, Ogura T, Kataoka H, et al: Differential effect of chronic inhibition of calcium channel and angiotensin II type 1-receptor on aldosterone synthesis in spontaneously hypertensive rats. J Steroid Biochem Mol Biol 2000; 74: 125-136.
46. Naruse M, Tanabe A, Sato A, et al: Aldosterone breakthrough during angiotensin II receptor antagonist therapy in stroke-prone spontaneously hypertensive rats. Hypertension 2002; 40: 28-33.
47. Mackie FE, Meyer TW, Campbell DJ: Effects of antihypertensive therapy on intrarenal angiotensin and bradykinin levels in experimental renal insufficiency. Kidney Int 2002; 61: 555-563.